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Gemcitabine is widely accepted as the standard treatment for pancreatic cancer, but it can cause unpredictable
side effects. Acute respiratory distress syndrome is a rare complication with gemcitabine, but is sometimes fatal. We
describe a cured case of acute, severe gemcitabine-induced pulmonary toxicity. The patient was a 76-year-old man
with pancreatic cancer who was receiving adjuvant gemcitabine chemotherapy after surgery. The patient received
gemcitabine 1,000 mg/m2 on days 1, 8, and 15 for three 4-week cycles, with intervals of 1 week. He developed
severe general fatigue on day 1 of the third cycle. Computed tomography showed diffuse ground-glass opacity
with pleural effusion. There was no increase in β-D-glucan, and cytomegalovirus antigenemia assays were negative.
No bacteria or acid-fast bacilli were found. The number of eosinophils in bronchoalveolar lavage fluid was
increased. Considering these data, we diagnosed eosinophilic pneumonia induced by gemcitabine. The patient was
immediately treated with a steroid and neutrophil elastase inhibitor under respiratory supportive therapy. After 4
weeks, his pulmonary symptoms were markedly improved. Physicians should be cognizant of the possible
association of serious pulmonary toxicity with gemcitabine treatment. A delay in diagnosis and treatment could
lead to a fatal outcome.
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Surgery is considered to be only curative option for
patients with resectable pancreatic cancer. However,
adjuvant therapy is considered to improve the surgical
outcome because there is the high recurrence rate of the
disease even after curative resection [1-4]. Gemcitabine
(2’,2’-difluoro-s’-deoxycytidine) is widely accepted as the
standard treatment for pancreatic cancer.
Two recent randomized phase III trials of adjuvant
chemotherapy have been conducted in patients with
resected pancreatic cancer. The CONKO-001 study
comparing surgery followed by gemcitabine with surgery
alone suggested that adjuvant gemcitabine did indeed
contribute to prolongation of disease-free survival, al-
though overall survival did not differ significantly* Correspondence: kashiwad@cc.saga-u.ac.jp
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reproduction in any medium, provided the orbetween the two groups [1]. The JSAP-02 study under-
taken in Japan showed similar results [5], differing only in
the planned number of gemcitabine cycles: three cycles of
gemcitabine were used in JSAP-02 in contrast to six
cycles in CONKO-001. The most common side effect of
gemcitabine is myelosuppression. Severe pulmonary
toxicity as a side effect is relatively rare, with a reported
incidence of between 0 and 5%, but 20% of patients with
severe pulmonary toxicity died [6].
We describe a rare case of potentially fatal severe
eosinophilic pneumonia induced by gemcitabine, which
was successfully treated.Case presentation
The patient was a 76-year-old manreceiving gemcitabine
chemotherapy for stage IIIA pancreatic cancer after
undergoing subtotal stomach-preserving pancreaticodu-
odenectomy for a tubular adenocarcinoma in the pan-
creas. Six weeks later, the patients was started on
gemcitabine (Gemzar®; Eli Lilly, Indianapolis, IN, USA) atLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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every 4 weeks. This 4-week cycle was repeated for three
cycles, with a 1-week interval between them, based on the
protocol used in the JSAP-02 study [5].
The patient developed severe general fatigue on day 1
of the third cycle. Arterial blood gas analysis showed
hypoxemia (PaO2 62 Torr with 8 l/min of oxygen by face
mask). His white blood cell count was 17.1 × 109/l with
80.7% neutrophils and 1.0% eosinophils. He reported
general fatigue and dyspnea but no cough.
On physical examination, the patient had negligible
crackles and poor inspiration in both lungs. Computed
tomography (CT) showed pleural effusion in both sides
of the thorax, and diffuse ground-glass opacity, thick-
ened septal line,s and diffuse reticular opacity in both
lungs (Figure 1). There was no increase in β-D-glucan,
and cytomegalovirus antigenemia assays were negative.
No bacteria or acid-fast bacilli were found. Pleural fluid
cytology was also negative for cancer cells. Laboratory
studies revealed that the patient’s lactate dehydrogenase
level was 253 U/l, KL-6 was 298 U/ml, and SP-D was
107 ng/ml. Antibiotics and sivelestat sodium hydrate
had been started on admission, under a working diagno-
sis of acute lung injury due to infection. However, the
patient’s respiratory status did not improve. Bronchoal-
veolar lavage (BAL) was performed for further differen-
tial diagnosis. The percentage of eosinophils in the BAL
fluid was raised (56%), strongly suggesting a diagnosis
of gemcitabine-induced acute eosinophilic pneumonia.
The patient was treated with methylprednisolone 1000
mg/day and sivelestat sodium hydrate for 3 days, with
methylprednisolone 40 mg/day for a further 11 days,
and then started on bi-level positive airway pressure
(BiPAP Vision®; Philips International, Amsterdam, The
Netherlands) by face mask to provide non-invasiveFigure 1 Chest computed tomography on admission. Bilateral
pleural effusion and diffuse ground-glass opacity was apparent, and
thickened septal lines and diffuse reticular opacity were evident in
both lungs.pressure support at 5 cm H20. After 4 weeks, there was
marked improvement in the pulmonary symptoms and
CT findings (Figure 2).
Gemcitabine is relatively well tolerated, and myelosup-
pression is generally the dose-limiting toxicity; pulmonary
toxicity with gemcitabine is relatively uncommon. The
incidence of grade 4 lung toxicity ranges from 0.06%, as
reported by an industry study based on commercial expos-
ure, to 8%, as reported in several case study reviews, and
the mortality rate is 20% [7,8]. In addition, gemcitabine-
induced eosinophilic pneumonia has been reported previ-
ously [9,10]. Thus, diagnosis of drug-induced pneumonia
has now become more important for patients with cancer.
We also investigated the prevalence of drug-induced
pneumonia in patients with pancreatic cancer or biliary
tract cancer. From data collected on 92 patients treated
with gemcitabine alone for pancreatic or biliary tract
cancer between January 2007 and December 2010 at our
institution (Table 1), the common reasons for treatment
delay were myelotoxic effects, infection, and emesis. Dis-
continuation because of grade 3 or 4 myelosuppression,
hepatobiliary disorder, and malaise occurred in 4 (4.0%) of
100 events. Drug-induced pneumonia as the main reason
for discontinuation accounted for two of six cases (33.3%)
in whom gemcitabine was discontinued, suggesting that
gemcitabine-induced pneumonia has significant morbidity
and mortality.
Pulmonary eosinophilic infiltrates are a heterogeneous
group of disorders characterized by the presence of eosin-
ophils in the lungs, as detected by BAL or tissue biopsy,
with or without blood eosinophilia. Pulmonary infiltrates,
characterized by foci of air-space consolidation and
focal ground-glass opacity, can be seen in pulmonary
eosinophilia of all causes [11]. The findings from CT
and careful clinical evaluation must correspond in orderFigure 2 Chest computed tomography at 4 weeks after starting
treatment. The ground-glass opacity in both lungs disappeared
after discontinuation of gemcitabine and initiation of corticosteroids
and pulmonary support.
Table 1 Reasons for delay or discontinuationin patients
who received gemcitabine systemic chemotherapy






gemcitabine, n = 6
Vomiting 5 (5.3) 0




Diarrhea 2 (2.1) 0
Malaise 4 (4.3) 1 (16.7)





Anemia 7 (7.4) 1 (16.7)
Platelet count
decreased










Hypoalbuminemia 2 (2.1) 0
Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase.
aTotal exceeds 92 because of the duplication of patients.
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pal method of confirming the diagnosis of acute eosino-
philic pneumonia. In such cases, eosinophils account
for more than 25% of the cells in the BAL fluid [12]. In
the present case, eosinophils showed an increase to 56%
on BAL analysis, and we ultimately used this finding to
reach the diagnosis of eosinophilic pneumonia.
Once the diagnosis has been made, the most common
treatment involves stopping gemcitabine and starting
high-dose steroids such as hydrocortisone, methylprednis-
olone, and dexamethasone, which are then tapered over
the course of several weeks alongside oxygen supplemen-
tation. In the present case, treatment was started using
sivelestat sodium hydrate (ONO-5046), a neutrophil elas-
tase inhibitor developed in Japan. Neutrophil elastase is a
protease produced by inflammatory cells, and its inhib-
ition is associated with the prevention of acute lung injury
(ALI) in animal models [13]. It has been suggested that
the physiopathological mechanism of drug-induced ALI is
a cytokine-mediated inflammatory reaction of the alveolar
capillary wall [14]. Although the importance of leukocyte
elastase relative to other proteases in the pathogenesis of
lung injury remains uncertain, we selected this drug on
the expectation of beneficial effects of elastase inhibition
for drug-induced ALI.Conclusion
We emphasize that physicians must be cognizant that of
the possible association of serious pulmonary toxicity
with gemcitabine treatment. A delay in diagnosis and
treatment of gemcitabine-induced severe eosinophilic
pneumonia could lead to a fatal outcome.
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